- 140 Downloads
Loratadine is a long-acting antihistamine agent, exhibiting partial selectivity for peripheral histamine H1-receptors. To date, loratadine has been evaluated in allergic rhinitis, urticaria and, to a limited extent, in asthma.
In several large controlled comparative clinical studies, loratadine was superior to placebo, faster acting than astemizole and as effective as azatadine, cetiri-zine, chlorpheniramine (chlorphenamine), clemastine, hydroxyzine, mequitazine and terfenadine in patients with allergic rhinitis and chronic urticaria. The clinical effectiveness of loratadine in asthma is at present unclear.
Loratadine is well tolerated. At dosages of 10mg daily, commonly reported adverse events were somnolence, fatigue and headache. Sedation occurred less frequently with loratadine than with azatadine, cetirizine, chlorpheniramine, clemastine and mequitazine. Serious ventricular arrhythmias, as reported with some other second generation histamine H1 -receptor antagonists, have not been observed with loratadine to date.
Thus, loratadine, with its attributes of once daily administration, fast onset of action and essentially nonsedating properties, would appear to be an appropriate first-line agent for the treatment of allergic rhinitis or urticaria.
Loratadine is a long-acting antihistamine agent which exhibits partial selectivity for histamine H1-receptors in vitro. It displays weak in vitro affinity for cholinergic receptors and α-adrenoceptors, while no anticholinergic effects have been observed in animal models.
In studies of its antihistaminic activity in humans, both the magnitude and duration of wheal suppression by loratadine in response to intradermally injected histamine are dose-related. Direct comparison of single doses of various histamine H1-receptor antagonists in healthy volunteers, using this standard model, revealed the following order of activity: cetirizine 10mg > terfenadine 120mg > terfenadine 60mg > loratadine 10mg > astemizole 10mg > chlorpheniramine (chlorphenamine) 4mg > placebo. Onset of antihistaminic action with loratadine, as measured by wheal and flare suppression, was apparent within the first hour of administration, and was sustained for up to 24 hours. Loratadine 10 to 20mg exhibits a protective effect on airways in response to inhaled histamine challenge in patients with asthma.
The antiallergic activity of loratadine has been demonstrated in humans, using cutaneous, nasal challenge and conjunctival provocation tests. Loratadine, however, does not attenuate early or late airways responses to inhaled allergens.
Significant ECG effects were not observed in guinea-pigs given single intravenous doses of loratadine up to 100mg/kg, or in healthy human volunteers given oral dosages of loratadine 40 mg/day for a period of 3 months. At dosages of up to 40 mg/day, loratadine does not appear to impair psychomotor function or potentiate the depressant effects of alcohol in healthy volunteers.
Following oral administration, loratadine is well absorbed, with peak plasma concentrations of 24.3 to 30.5 μg/L occurring between 1 and 1.5 hours after ingestion of a 40mg capsule. Both loratadine and its major active metabolite, descarboethoxyloratadine (DCL) exhibit dose proportional pharmacokinetics after single- and multiple-dose administration.
Loratadine is 97 to 99% plasma protein bound and has a large volume of distribution (119 L/kg). Distribution half-lives (t1/2α) in both single- (20 and 40mg) and multiple-dose loratadine studies (40mg once daily) range from 0.9 to 1.0 hours. While loratadine is excreted into breastmilk, the amount of an administered dose appearing in the milk is minimal.
Loratadine is extensively metabolised by hydroxylation. Plasma elimination half-lives (t1/2β) of loratadine in single-dose studies (20 to 40mg) ranged from 7.8 to 11 hours. At steady-state, a t1/2β value of 14.4 hours was documented following administration of loratadine 40 mg/day for 10 days. Haemodialysis appears to have a negligible effect on loratadine clearance.
Although ketoconazole, erythromycin and cimetidine inhibit the metabolism of loratadine, these pharmacokinetic interactions appear to be of little or no clinical significance. Where ECG parameters were measured, adverse cardiovascular effects were not observed as a result of elevated plasma concentrations of loratadine or DCL.
In large comparative trials of patients with seasonal allergic rhinitis, short term therapy (2 to 3 weeks) with loratadine at therapeutic doses was significantly superior to placebo, and as effective as azatadine, cetirizine, clemastine, mequitazine or terfenadine. Loratadine was faster acting than astemizole, and was effective in relieving nasal, conjunctival and other non-nasal symptoms. Combination therapy with loratadine 10mg and pseudoephedrine 240mg (as a single daily dose or in 2 divided doses) may further improve nasal symptoms associated with allergic rhinitis. In children and/or adolescents with seasonal allergic rhinitis, loratadine was as effective as astemizole, chlorpheniramine, dexchlorpheniramine and terfenadine in alleviating symptoms, but less effective than intranasal fluticasone in relieving symptoms of nasal blockage.
Similarly, at therapeutic doses loratadine was as efficacious as clemastine or terfenadine over treatment periods of up to 6 months in perennial rhinitis: nasal stuffiness, post-nasal drainage and nasal discharge were reduced by approximately 50% with loratadine.
Comparable symptomatic improvement was noted with therapeutic doses of loratadine, clemastine, hydroxyzine and terfenadine over treatment periods of up to 12 weeks in patients with chronic urticaria. Preliminary data also suggest that adjuvant treatment with loratadine may relieve pruritic symptoms in patients with atopic dermatitis.
In acute coryza, combined therapy with loratadine 5mg and pseudoephedrine 120mg as 1 tablet taken twice daily may provide some symptomatic relief. Whether this combination provides additional relief of cold symptoms over pseudoephedrine monotherapy remains to be confirmed.
The clinical effectiveness of loratadine in the treatment of asthma remains unclear. Conflicting results and small patient numbers in studies conducted to date provide inconclusive results and thus do not support its use in asthma at present.
Loratadine is generally well tolerated at therapeutic doses in adults, elderly patients and children. In a review of 15 noncomparative studies in which some 55 000 patients received loratadine 10 mg/day, commonly reported adverse events were somnolence, fatigue and headaches (≈ 1%), while dry mouth and gastrointestinal upset occurred less frequently. Loratadine was less sedating than azatadine, cetirizine, clemastine, chlorpheniramine and mequitazine.
Serious ventricular arrhythmias, reported with some second generation histamine H1-receptor antagonists (e.g. terfenadine and astemizole), have not been observed with loratadine to date, although rare cases of supraventricular tachycardia have been reported.
The tolerability of a combination preparation of loratadine 5mg with pseudo-ephedrine 120mg, taken twice daily, was comparable with pseudoephedrine monotherapy, but produced a significantly greater incidence of dry mouth and insomnia in comparison with placebo and loratadine alone.
In reported cases of overdosage with loratadine, recovery was uneventful. Accidental overdosage in 5 young children at loratadine dosages 10 to 20 times greater than those recommended produced no adverse cardiac events.
Dosage and Administration
At present, loratadine is indicated for the relief of symptoms associated with allergic rhinitis, urticaria and other allergic dermatological disorders. The recommended dose of loratadine is 10mg once daily for adults and for children weighing more than 30kg. Children aged 2 to 12 years and weighing less than 30kg should receive 5mg once daily.
In adults, 1 combination tablet (loratadine 5mg and pseudoephedrine 120mg) is recommended twice daily for symptomatic relief of the common cold.
Although dosage adjustments may be necessary in patients with hepatic impairment, this is unlikely to be required in either elderly patients or those with renal impairment.
Unable to display preview. Download preview PDF.
- 3.Leysen JE, Gommeren W, Janssen PFM, et al. Anti-histaminiques non-sedatifs et liaison aux récepteurs histaminergiques-H1 centraux et périphériques [in French]. Allergie Immunol 1991; 23: 51–7Google Scholar
- 7.Berthon B, Combettes L, Czarlewski W, et al. In vitro inhibition by loratadine and descarboxyethoxyloratadine of histamine release from human basophils and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3) [abstract 2493]. Allergy 1993; 48 Suppl. 16: 190Google Scholar
- 8.Weyer A, Czarlewski W, Carmi-Leroy A, et al. In vitro inhibition by loratadine and its active metabolite of anti-IgE induced histamine release from human basophils [abstract 312]. J Allergy Clin Immunol 1992; 89: 222Google Scholar
- 11.Simons FER, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol 1990; 86: 540–7PubMedGoogle Scholar
- 17.Simons FER, Lukowski JL, Becker AB, et al. Comparison of the effects of single doses of new H1-receptor antagonists loratadine and terfenadine versus placebo in children. J Pedi-atr 1991; 118: 298–300Google Scholar
- 19.Debelic M. Protection against histamine-induced bronchocon-striction by loratadine. Allergol Immunopathol 1992; 20: 97–100Google Scholar
- 24.Bousquet J, Lebel B, Chanal I, et al. Anti-allergic activity of loratadine and terfenadine assessed by nasal challenge [abstract 241]. J Allergy Clin Immunol 1988; 81: 228Google Scholar
- 26.Skassa-Brociek W, O’Quigley J, Blizard R, et al. Differentiation between the anti-allergic and antihistaminic effects of loratadine (L) and astemizole (A) by skin tests. J Allergy Clin Immunol 1988; 8: 175Google Scholar
- 28.Miadonna A, Milazzo N, Lorini M, et al. Inhibitory effect of loratadine on iLTC4 release from human leukocytes [abstract 208]. J Allergy Clin Immunol 1993; 91: 193Google Scholar
- 29.Grönneberg R, Raud J, Roquet A, et al. Effect of loratadine on IgE-mediated skin reactions and mediator release and inflammatory events in skin chambers in atopics [abstract 1238]. Allergy 1993; 48 Suppl. 16: 35Google Scholar
- 31.Gunia NA, Kikvidze MS. Application of Claritin (loratadine) in allergic rhinitis [abstract 1237]. Allergy 1993; 48 Suppl. 16: 35Google Scholar
- 32.Raptopoulou-Gigi M, Ilonidis G, Orphanou-Koumerkeridou H, et al. The effect of loratadine on activated cells of the nasal mucosa in patients with allergic rhinitis. J Invest Allergol Clin Immunol 1993; 3: 192–7Google Scholar
- 33.Cuss F, Kreutner W, Danzig M, et al. Loratadine, a non-sedating antihistamine, inhibits allergen-induced nasal vaso-permeability [abstract P242]. Clin Exp Allergy 1990; 20 Suppl. 1: 99Google Scholar
- 44.Moser L, Plum H, Buckmann M. Lack of potentiation of the effect of alcohol by loratadine. XIIIth Congress of the European Academy of Allergology and Clinical Immunology; 1986 May; BudapestGoogle Scholar
- 46.Riedel WJ, Schoenmakers EA, O’Hanlon JF. The effects of loratadine alone and in combination with alcohol on actual driving performance. University of Limburg, Maastricht: Institute for Drugs, Safety and Behaviour, 1987.Google Scholar
- 53.Chen Y, Woosley RL. Electrophysiologic actions of astemizole [abstract PI-93]. Clin Pharmacol Ther 1994; 55: 146Google Scholar
- 54.Hey JA, del Prado M, Chapman RW, et al. Loratadine produces antihistamine activity without adverse CNS or cardiovascular effects in guinea pigs: comparative studies with sedating and nonsedating H1 antihistamines [abstract 5]. J Allergy Clin Immunol 1994; 93: 163Google Scholar
- 55.Hey JA, del Prado M, Egan RW, et al. Loratadine produces antihistamine activity without adverse CNS or cardiovascular effects in guinea pig [abstract 226]. In: Allergy and Clinical Immunology News (Suppl. 2), 1994 (Proceedings of the 15th International Congress of Allergology and Clinical Immunology and the Annual Meeting of the European Academy of Allergology and Clinical Immunology; 1994 Jun 26–Jul 1; Stockholm)Google Scholar
- 56.Affrime MB, Lorber R, Danzig M, et al. Three month evaluation of electrocardiographic effects of loratadine in humans [abstract 1215]. Allergy 1993; 48 Suppl. 16: 29Google Scholar
- 57.Schering-Plough Pty Ltd. Loratadine prescribing information. Otahuhu, New Zealand, 1992Google Scholar
- 63.Katchen B, Cramer J, Chung M, et al. Disposition of 14C-SCH 29851 in humans [abstract 669]. Ann Allergy 1985; 55: 393Google Scholar
- 65.Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistaminic drug loratadine [abstract 429]. J Allergy Clin Immunol 1994; 93: 234Google Scholar
- 66.Lavrijsen K, Van Houdt J, Meuldermans W, et al. The interaction of ketoconazole, itraconazole and erythromycin with the in vitro metabolism of antihistamines in human liver microsomes [abstract 1233]. Allergy 1993; 48 Suppl. 16: 34Google Scholar
- 67.Van Peer A, Crabbé R, Woestenborghs R, et al. Ketoconazole inhibits loratadine metabolism in man [abstract 1234]. Allergy 1993; 48 Suppl. 16: 34Google Scholar
- 68.Brannan M, Reidenberg P, Radwanski E, et al. Evaluation of pharmacokinetic and electocardiographic parameters following 10 days of concomitant administration of loratadine with erythromycin [abstract 1895]. In: Allergy and Clinical Immunology News, (Suppl. 2), 1994 (Proceedings of the 15th International Congress of Allergology and Clinical Immunology and the Annual Meeting of the European Academy of Allergology and Clinical Immunology; 1994 Jun 26–Jul 1; Stockholm)Google Scholar
- 69.Brannan MD, Affrime MB, Reidenberg P, et al. Evaluation of the pharmacokinetics and electrocardiographic pharmacokinetics of loratadine with concomitant administration of cimetidine [abstract 8]. Pharmacotherapy 1994; 14: 347Google Scholar
- 71.Roman LS. Onset of action of loratadine in seasonal allergic rhinitis. Today’s Ther Trends 1988; 6: 19–27Google Scholar
- 72.Bousquet J. Clinical activity and side effects of loratadine and astemizole in patients with seasonal allergic rhinitis. 44th Annual Congress, American College of Allergists; 1987 Nov; BostonGoogle Scholar
- 75.Herman D, Arnaud A, Dry J, et al. Clinical effectiveness and safety of loratadine vs. cetirizine in the treatment of seasonal allergic rhinitis [abstract OP80]. Clin Exp Allergy 1990; 20 Suppl. 1: 56Google Scholar
- 76.Herman D, Arnaud A, Dry J, et al. Efficacité clinique et tolérance de la loratadine versus cetirizine dans le traitement de la rhinite allergique saisonnière [in French]. Allergie Immunolog 1992; 24: 270–4Google Scholar
- 77.Tjwa MKT, Widjaja P, DelBono L, et al. Loratadine compared to cetirizine in patients with seasonal allergic rhinitis [abstract 153271]. Allergy 1992; 47 Suppl. 12: 174Google Scholar
- 78.Siegel S, Ellis E, Kemp J, et al. Efficacy and safety of loratadine in the treatment of allergic rhinitis in children [abstract A-2]. Allergy 1988; 43 Suppl. 7: 5Google Scholar
- 80.Kemp JP, Bahna SL, Chervinsky P, et al. A comparison of loratadine, a new nonsedating antihistamine, with clemastine and placebo in patients with fall seasonal allergic rhinitis. Am J Rhinol 1987; 1: 151–4Google Scholar
- 88.Jordana G, Dolovich J, Briscoe M, et al. Fluticasone propionate (FP) vs loratadine (L) in adolescents with seasonal allergic rhinitis (SAR): nasal obstruction and peak inspiratory flow (PIF) [abstract 654]. J Allergy Clin Immunol 1993; 93: 271Google Scholar
- 89.Bronsky E, Lorber R, Danzig M. Additive activity of loratadine (L) and pseudoephedrine (PS) in a once daily (QD) formulation in patients with seasonal allergic rhinitis (SAR) [abstract 1248]. Allergy 1993; 48 Suppl. 16: 38Google Scholar
- 90.Hébert J, Bédard P-M, Carpio JD, et al. Loratadine and pseudoephedrine sulfate: a double-blind, placebo-controlled comparison of a combination tablet (SCH 434) and its individual components in seasonal allergic rhinitis. Am J Rhinol 1988; 2: 71–5Google Scholar
- 91.Hébert J, Drouin M, Gutkowski A, et al. A double-blind, placebo-controlled study of the effect of SCH 434 compared to its components in patients with seasonal allergic rhinitis. Rev Esp Alergol Immunol Clin 1987; 2: 137Google Scholar
- 95.Del Giacco S, Locci F, Meloni G, et al. Perennial allergic rhinitis treated with a non-sedating new antihistamine loratadine. Allergy 1988; 43 Suppl. 7: 111Google Scholar
- 96.Horak F, Bruttmann G, Charpin J, et al. Effects of loratadine in patients with perennial allergic rhinitis. Rev Esp Alergol Immunol Clin 1987; 2: 323Google Scholar
- 97.Pleskow WW. Studies of a new antihistamine in the management of perennial allergic rhinitis and chronic idiopathic urticaria [abstract]. 44th Annual Congress, American College of Allergists; 1987 Nov 15; BostonGoogle Scholar
- 99.Friedman HM. Loratadine: a potent, nonsedating, and long-acting H1-antagonist. Am J Rhinol 1987; 1: 95–9Google Scholar
- 104.Bernstein IL, Bernstein DI. The efficacy and safety of loratadine in the management of chronic idiopathic urticaria. J Allergy Clin Immunol 1988; 81: 211Google Scholar
- 107.Peter RU, Ring J. Antihistaminika bei Juckenden Dermatosen. Doppelblinder Vergleich von Loratadin mit Clemastin [in German]. Münch Med Wochenschr 1989; 131: 660–2Google Scholar
- 108.Soto LD, Falabella R, Hojyo T, et al. Estudio multicéntrico comparativo entre dos antihistaminicos anti H1 en el manejo de dermatosis crónicas pruriginosas [in Spanish]. Dermatol Rev Mex 1987; 31: 9–14Google Scholar
- 112.Perrin-Fayolle M, Bousquet J, Kroll VM, et al. Loratadine (L) vs ketotifen (K) in the treatment of seasonal asthma [abstract 1221]. Allergy 1993; 48 Suppl. 16: 31Google Scholar
- 113.Rosário NA, Kantor Jr O. Acute bronchodilator effect of loratadine in asthmatic children [abstract 1240]. Allergy 1993; 48 Suppl. 16: 36Google Scholar
- 114.Menardo JL, Clavel R, Couturier P, et al. Evaluation of prophylactic treatment with loratadine (L) vs sodium cromoglycate (SC) in allergic children with mild to moderate bronchial asthma [abstract 1220]. Allergy 1993; 48 Suppl. 16: 31Google Scholar
- 115.Van Cauwenberge PB. New data on the safety of loratadine. Drug Invest 1992; 4: 283–91Google Scholar
- 116.Bruttmann G, Pedrali P. Loratadine SCH 29851 and the treatment of seasonal allergic rhinitis (pollinosis). Ann Allergy 1985; 55: 233Google Scholar